Streetbeat News

BNTC

Benitec Biopharma Inc.

https://benitec.com

Industry

Biotechnology

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Open

9.38

Mkt cap

229M

Volume

39K

High

10.11

P/E Ratio

-3.36

52-wk high

12.89

Low

9.10

Div yield

N/A

52-wk low

2.69

Guggenheim has initiated coverage on Benitec Biopharma with a Buy rating and set a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 11:51 am

Leerink Partners has initiated coverage on Benitec Biopharma (NASDAQ:BNTC) with an Outperform rating and a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 10:29 am

Piper Sandler has initiated coverage on Benitec Biopharma (NASDAQ:BNTC) with an Overweight rating and a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 9:29 am

Health care stocks showed significant movement in Monday's intraday session, with notable gainers including CareCloud, Novavax, and Macrogenics, and losers like TransCode Therapeutics and Applied DNA Sciences. Earnings reports influenced several stock movements.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 4:31 pm

Benitec Biopharma's shares dropped following the announcement of disappointing Q3 GAAP EPS results and a decline in Q3 revenue year-over-year.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 3:32 pm

Benitec Biopharma reported a Q3 2024 revenue of $0, a significant drop from the previous year's $54,000. This indicates a challenging period for the company, potentially impacting its financial stability and investor confidence.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:19 pm

Benitec Biopharma reported a Q3 2024 GAAP EPS loss of $(1.64), missing the consensus estimate of $(0.78) by 110.26%.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:18 pm

Steven Oliveira has reported a passive stake of 8.89% in Benitec Biopharma as of April 22, according to a 13G filing with the SEC.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 3:48 pm

JMP Securities analyst Silvan Tuerkcan has maintained a Market Outperform rating on Benitec Biopharma (NASDAQ:BNTC) and raised the price target from $10 to $16.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 4:17 pm

In Thursday's after-market session, several healthcare stocks experienced significant movements. Bio-Path Holdings, Biora Therapeutics, Mustang Bio, BIMI International Medical, Allarity Therapeutics, and China SXT Pharmaceuticals were among the gainers, with increases ranging from 6.06% to 9.0%. Conversely, Virpax Pharmaceuticals, iSpecimen, Portage Biotech, SINTX Technologies, Cyclo Therapeutics, and Benitec Biopharma saw declines between 6.16% and 18.2%.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.